Generation Bio Co (NAS:GBIO)
$ 2.64 -0.13 (-4.69%) Market Cap: 176.20 Mil Enterprise Value: 53.21 Mil PE Ratio: 0 PB Ratio: 1.61 GF Score: 34/100

Generation Bio Co at Jefferies Cell & Genetic Medicine Summit Transcript

Sep 26, 2023 / 01:30PM GMT
Release Date Price: $3.68 (+0.82%)
Nalin Tejavibulya
Jefferies LLC - Analyst

Today, it is my great pleasure to host a fireside chat with Geoff McDonough, President and CEO of Generation Bio. Thank you very much for joining us.

Questions & Answers

Nalin Tejavibulya
Jefferies LLC - Analyst

So to begin, Geoff, could you please provide a quick overview of Generation Bio and Generation Bio's differentiated non-viral gene therapy platform?

Geoff McDonough
Generation Bio Co. - President and CEO

Thank you, Nalin, for the invitation to be here and for hosting. It's a pleasure to join you guys.

The way we think about non-viral, genetic medicine is in three waves of modality evolution. The first was originated by Alnylam, which is silencing RNA. They provided redosable, durable loss of function or knockdown. And the next wave of that non-viral, genetic medicine evolution came with Moderna and others, bringing messenger RNA, which was also redosable, but really brought gain of function to genetic medicines, and traded off durability with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot